08:19 AM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday it yielded positive overall survival data in a phase 2 late-stage metastatic breast cancer study evaluating Bria-IMT in combination with an immune check point inhibitor.

The 54-patient study showed median survival of 15.6 months in patients treated with Bria-MT compared with 6.7 to 9.3 months for patients in other studies.

The biotechnology company said the median overall survival of 15.6 months "represents a substantial improvement" relative to prior overall survival data reported in December 2023.

Shares of the company were up more than 98% in recent premarket trading.

Price: 1.2300, Change: +0.61, Percent Change: +98.42